
AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg
AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg, is the first and only brand prescription medicine indicated to help improve walking in adults with multiple sclerosis (MS).
What is AMPYRA® (dalfampridine)?
AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg, is the first and only brand prescription medicine indicated to help improve walking in adults with multiple sclerosis (MS).
Is AMPYRA® (dalfampridine) Right For You?
AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, is the first and only brand prescription medicine indicated to help improve walking in adults with multiple sclerosis (MS).
Dosing Information | AMPYRA® (dalfampridine)
To get the optimum efficacy from AMPYRA, it's important that you take the right dose at the right time. See dosing instructions and full safety and prescribing information.
Walking and MS: Your Moment of Truth - AMPYRA
AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg, is the first and only brand prescription medicine indicated to help improve walking in adults with multiple sclerosis (MS). …
This Medication Guide summarizes the most important information about AMPYRA. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for …
Help with AMPYRA Coverage
Find out about MyAmpyra patient support and see if you are eligible to pay as little as $0 for AMPYRA® (dalfampridine) through the co-pay savings program.
Getting Started on AMPYRA
AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, is the first and only brand prescription medicine indicated to help improve walking in adults with multiple sclerosis (MS).
Real Patient Videos | AMPYRA® (dalfampridine)
Watch videos of real AMPYRA® (dalfampridine) patients before and after starting treatment. See Important Safety Information and Medication Guide.
Help With AMPYRA Coverage
AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg, is the first and only brand prescription medicine indicated to help improve walking in adults with multiple sclerosis (MS).